AB Soft ii manual

induced pain flare after palliative radiotherapy for bone metastases-a pilot study. Support Care Cancer 15(6): 643-647, 6/2007.

8.Cleeland CS. The measurement of pain from metastatic bone disease: capturing the patient's experience. Clin Cancer Res 12(20 Pt 2): 6236s-6242s, 10/2006.

9.Colella J, Scrofine S, Galli B, Knorr-Mulder C, Gejerman G, Scheuch J, Lanteri V, Siegel A, Levey S, Watson R, Block M, Sawczuk I. Prostate HDR radiation therapy: a comparative study evaluating the effectiveness of pain management with peripheral PCA vs. PCEA. Urol Nurs 26(1): 57-61, 2/2006.

10.Depuy V, Anstrom KJ, Castel LD, Schulman KA, Weinfurt KP, Saad F. Effects of skeletal morbidities on longitudinal patient- reported outcomes and survival in patients with metastatic prostate cancer. Support Care Cancer 15(7): 869-876, 7/2007.

11.Goetz MP, Callstrom MR, Charboneau JW, Farrell MA, Maus TP, Welch TJ, Wong GY, Sloan JA, Novotny PJ, Petersen IA, Beres RA, Regge D, Capanna R, Saker MB, Gronemeyer DH, Gevargez A, Ahrar K, Choti MA, de Baere TJ, Rubin J. Percutaneous image-guided radiofrequency ablation of painful metastases involving bone: a multicenter study. J Clin Oncol 22(2): 300-306, 1/2004.

12.Hadi S, Fan G, Hird AE, Kirou-Mauro A, Filipczak LA, Chow E. Symptom clusters in patients with cancer with metastatic bone pain. J Palliat Med 11(4): 591-600, 5/2008.

13.Halabi S, Vogelzang NJ, Kornblith AB, Ou SS, Kantoff PW, Dawson NA, Small EJ. Pain predicts overall survival in men with metastatic castration-refractory prostate cancer. J Clin Oncol 26(15): 2544-2549, 5/2008.

14.Harris K, Pugash R, David E, Yee A, Sinclair E, Myers J, Chow E. Percutaneous cementoplasty of lytic metastasis in left acetabulum. Curr Oncol 14(1): 4-8, 2/2007.

15.Harris K, Li K, Flynn C, Chow E. Worst, average or current pain in the brief pain inventory: Which should be used to calculate the response to palliative radiotherapy in patients with bone metastases? Clinical Oncology 19(7): 523-527, 9/2007.

16.Hartsell WF, Scott CB, Bruner DW, Scarantino CW, Ivker RA, Roach M, III, Suh JH, Demas WF, Movsas B, Petersen IA, Konski AA, Cleeland CS, Janjan NA, DeSilvio M. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97(11): 798-804, 6/2005.

17.Hong SJ, Cho KS, Choi HY, Ahn H, Kim CS, Chung BH. A prospective, multicenter, open-label trial of zoledronic acid in patients with hormone refractory prostate cancer. Yonsei Medical Journal 48(6): 1001-1008, 12/2007.

18.Janjan NA, Payne R, Gillis T, Podoloff D, Libshitz HI, Lenzi R, Theriault R, Martin C, Yasko A. Presenting symptoms in patients referred to a multidisciplinary clinic for bone metastases. J Pain Symptom Manage 16(3): 171-178, 9/1998.

19.Kornblith AB, Herndon JE, Zuckerman E, Godley PA, Savarese D, Vogelzang NJ. The impact of docetaxel, estramustine, and low dose hydrocortisone on the quality of life of men with hormone refractory prostate cancer and their partners: a feasibility study. Ann Oncol 12(5): 633-641, 5/2001.

20.Loblaw A, Chow E, Panzarella T, Tsao M, Barnes EA, Sinclair E, Farhadian M, Danjoux C. Dexamethasone for the prophylaxis of radiation-induced pain flare following palliative radiotherapy for bone metastases. Int J Radiat Oncol Biol Phys 66(3 Supplement 1): S525, 11/2006.

21.Lothman H, Heatley S, Lipton A. Zoledronic acid (zol) provides long-term palliation of bone pain in breast cancer (bc) patients (pts) with bone metastases. Eur J Oncol Nurs 10(3): 225-226, 7/2006.

22.Mystakidou K, Katsouda E, Parpa E, Kouskouni E, Chondros C, Tsiatas ML, Galanos A, Vlahos L. A prospective randomized controlled clinical trial of zoledronic acid for bone metastases. Am J Hosp Palliat Care 23(1): 41-50, 1/2006.

23.Nishio M, Sano M, Tamaki Y, Fujii H, Shima Y, Fujimoto H, Kubo A, Koizumi K, Tokuda Y, Adachi S, Sumiyoshi Y, Hasegawa T, Eguchi K. [A multicenter study to determine the efficacy and safety of strontium (89Sr) chloride for palliation of painful bony

17 18